Turkey With an already well-established manufacturing industry for pharmaceuticals, Turkey has been aiming to move with global trends and invest in biologics production, specifically in biosimilars. The share of biotechnological pharmaceuticals has reached 30 percent globally, a rate that is expected to continue increasing, but the market share in Turkey…
Turkey When the Turkish Ministry of Health implemented its strategy to transition from import pharmaceuticals to manufacturing them at home in 2016, the local industry leveraged the situation to invest in new technology and increase their manufacturing capacity. A few multinational innovators took the opportunity to invest in their own plants,…
Turkey There are perhaps no two words that better summarize the last few years in Turkish pharma than localization and pricing. But after years of investment and struggles, the country’s priorities appear to be shifting. Turkey’s Vision 2023, as defined in its 11th Development Plan, has changed the government’s vision regarding…
Turkey While supporters of Turkey’s localization policy for pharmaceuticals implemented in 2016 applaud the changes it has brought, its opponents are awaiting a much-anticipated report by the World Trade Organization that could put an end to the policy and have global repercussions. Five years after the launch of Turkey’s localization…
Turkey Almost two decades after initiating large-scale health system reforms, Turkey has consolidated the provision of universal healthcare coverage to over 95 percent of the population. The effort, part of the country’s Health Transformation Program introduced in 2003, has been commended by international organizations across the world. But today, as citizens…
Turkey The secretary general for Turkey’s Pharmaceutical Manufacturers Association (IEIS), Savaş Malkoç, highlights their objective of increasing R&D expenditure and Turkey’s big opportunity ahead in biosimilars production. In addition, Malkoç discusses the persisting issues within the country’s pricing and reimbursement system and why localization policies have been a net gain for…
Turkey Despite the sharp decline in the Turkish lira’s value, the general mood among pharmaceutical executives in Turkey is positive. Rather than being discouraged, they are calling upon their resiliency and experience from former periods of economic fluctuation to push the Turkish healthcare and life sciences sector forward. Turkey made…
Turkey Turgut Tokgöz, secretary general of the Pharmaceutical Manufacturers Association of Turkey (IEIS), provides his take on the state of the Turkish pharmaceutical sector, highlighting the challenges that the industry faces with domestic pricing policy, the currency crisis of the Turkish Lira, and the barriers hindering Turkish firms from entering the…
Pharmaceutical Manufacturers Association of Turkey (IEIS) IEIS is an association with dual responsibilities. Promotion of generic usage in turkey and ensuring the sustained development of a local manufacturing industry. Before we look into these two aspects, I would like you to give us your perspective on the future role of the association, in an environment where…
See our Cookie Privacy Policy Here